The Colorado Prescription Drug Affordability Board (PDAB) selected five prescription drugs for its first affordability reviews at its Aug. 4th meeting.  The drugs and their primary treatments that will enter affordability reviews and be considered for upper payment limits (UPL) are as follows:  Enbrel (rheumatoid and psoriatic arthritis) Genvoya (human immunodeficiency virus) Cosentyx (plaque psoriasis … Read more

The Prescription Drug Affordability Advisory Council (PDAAC) held its most recent meeting on July 13th to develop a recommendation of 20 drugs for consideration of upper payment limits (UPL) by the Prescription Drug Affordability Board (PDAB).      The Department of Regulatory Affairs has created an interactive, user-focused dashboard for its list of drugs eligible … Read more

On Friday, the Colorado Prescription Drug Affordability Board (PDAB) unanimously approved the eligible drug list that will be subject to its review process for establishing upper payment limits (UPL) on prescription drugs.      The list contains hundreds of drugs that were chosen based on the approved selection criteria: the total utilization of the drug, … Read more

During a virtual stakeholder meeting last Wednesday, the Colorado Division of Insurance presented its proposed methodology for establishing upper payment limits (UPL) on prescription drugs the Prescription Drug Affordability Board (PDAB) has determined to be unaffordable.      Under the proposed rules, commercially insured Coloradans’ out-of-pocket expense and  health plans’ reimbursement to the pharmacy and … Read more